Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Elevated incidence of chronic myeloid leukaemia in immunosuppressed solid organ transplant recipients.

Dhanarajan A, Hsu JW, le Coutre P, Wingard JR, Chang M, Norkin M.

Br J Haematol. 2014 Aug;166(4):619-21. doi: 10.1111/bjh.12885. Epub 2014 Apr 4. No abstract available.

PMID:
24697357
2.

BCR-ABL positive cells and chronic myeloid leukemia in immune suppressed organ transplant recipients.

le Coutre P, Reinke P, Neuhaus R, Trappe R, Ringel F, Lalancette M, Hemmati PG, Dörken B, Daniel PT.

Eur J Haematol. 2010 Jan 1;84(1):26-33. doi: 10.1111/j.1600-0609.2009.01357.x. Epub 2009 Oct 3.

PMID:
19799626
3.

[Chronic myeloid leukemia after renal transplantation: report of a new case and review of the bibliography].

Sanz L, Cervantes F, Esteve J, Vilardell J, Marín P, Rozman C, Montserrat E.

Sangre (Barc). 1996 Oct;41(5):391-3. Spanish.

PMID:
9026925
4.

[Chronic myeloid leukemia after kidney transplantation].

Fernández-Avilés F, Ribera JM, Batlle M, Lauzurica R.

Sangre (Barc). 1997 Feb;42(1):85-6. Spanish. No abstract available.

PMID:
9229811
5.

Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning.

Majhail NS, Brazauskas R, Rizzo JD, Sobecks RM, Wang Z, Horowitz MM, Bolwell B, Wingard JR, Socie G.

Blood. 2011 Jan 6;117(1):316-22. doi: 10.1182/blood-2010-07-294629. Epub 2010 Oct 6.

6.

Chronic myeloid leukemia following heart transplantation and immunosuppression with tacrolimus.

Sbenghe MM, Florea AD, Mather P, Gitelson E.

Clin Adv Hematol Oncol. 2011 Aug;9(8):623-7. No abstract available.

PMID:
22236991
7.

Chronic myeloid leukemia following kidney transplantation.

Pelloso LA, Campos MG, Nascimento M, Silva MR, Pestana JO, Chauffaille Mde L.

Leuk Res. 2005 Mar;29(3):353-5.

PMID:
15661273
8.

Relapse after non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: early transplantation, use of an unrelated donor, and chronic graft-versus-host disease are protective.

Enright H, Davies SM, DeFor T, Shu X, Weisdorf D, Miller W, Ramsay NK, Arthur D, Verfaillie C, Miller J, Kersey J, McGlave P.

Blood. 1996 Jul 15;88(2):714-20.

9.

Chronic myelogenous leukemia following kidney transplantation in a pediatric patient.

Mignozzi M, Picca S.

Pediatr Nephrol. 2001 Nov;16(11):852-3.

PMID:
11685587
10.

Donor chimaerism is a strong indicator of disease free survival following bone marrow transplantation for chronic myeloid leukaemia.

Gardiner N, Lawler M, O'Riordan J, De'Arce M, McCann SR.

Leukemia. 1997 Apr;11 Suppl 3:512-5.

PMID:
9209441
11.

Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination.

Carlens S, Ringdén O, Aschan J, Hägglund H, Ljungman P, Mattsson J, Remberger M.

Clin Transplant. 1998 Apr;12(2):84-92.

PMID:
9575394
12.

Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. French Society of Bone Marrow Transplantation.

Guardiola P, Kuentz M, Garban F, Blaise D, Reiffers J, Attal M, Buzyn A, Lioure B, Bordigoni P, Fegueux N, Tanguy ML, Vernant JP, Gluckman E, Socié G.

Br J Haematol. 2000 Oct;111(1):292-302.

PMID:
11091216
13.

Kinetics of stem cell engraftment and clearance of leukaemia cells after allogeneic stem cell transplantation with reduced intensity conditioning in chronic myeloid leukaemia.

Kreuzer KA, Schmidt CA, Schetelig J, Held TK, Thiede C, Ehninger G, Siegert W.

Eur J Haematol. 2002 Jul;69(1):7-10.

PMID:
12270056
14.

Prediction of relapse by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukemia.

Asnafi V, Rubio MT, Delabesse E, Villar E, Davi F, Damaj G, Hirsch I, Dhédin N, Vernant JP, Varet B, Buzyn A, Macintyre E.

Leukemia. 2006 May;20(5):793-9.

PMID:
16541140
15.

Factors affecting risk of relapse and leukemia-free survival in HLA-identical sibling marrow transplant recipients with leukemia.

Carlens S, Ringdén O, Remberger M, Mattsson J, Aschan J, Hägglund H, Ljungman P.

Transplant Proc. 1997 Nov;29(7):3147-9. No abstract available.

PMID:
9365702
16.

T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.

Drobyski WR, Hessner MJ, Klein JP, Kabler-Babbitt C, Vesole DH, Margolis DA, Keever-Taylor CA.

Blood. 1999 Jul 15;94(2):434-41. Erratum in: Blood 2000 Feb 15;95(4):1137.

17.

Myeloid leukaemia in systemic lupus erythematosus--a nested case-control study based on Swedish registers.

Löfström B, Backlin C, Sundström C, Hellström-Lindberg E, Ekbom A, Lundberg IE.

Rheumatology (Oxford). 2009 Oct;48(10):1222-6. doi: 10.1093/rheumatology/kep204. Epub 2009 Jul 16. Review.

PMID:
19608725
18.

Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia.

Holowiecki J, Giebel S, Wojnar J, Krawczyk-Kulis M, Markiewicz M, Holowiecka-Goral A, Freund M, Casper J.

Br J Haematol. 2008 Jun;142(2):284-92. doi: 10.1111/j.1365-2141.2008.07179.x. Epub 2008 May 19.

PMID:
18492101
20.

High-dose busulphan alone as cytoreduction before allogeneic or autologous stem cell transplantation for chronic myeloid leukaemia: a single-centre experience.

Olavarria E, Kanfer E, Szydlo R, O'Brien S, Craddock C, Apperley J, Goldman J.

Br J Haematol. 2000 Mar;108(4):769-77.

PMID:
10792282

Supplemental Content

Support Center